NEW YORK CITY, NY / ACCESS Newswire / March 16, 2025 / WHY: Rosen Law Firm, a global investor rights law firm, reminds ...

To join the GSK class action, go to https://rosenlegal.com/submit-form/?case_id=34609 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class ...

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Glaxo (GSK) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

GSK acquired Zejula as part of its $5.1 billion takeover of Tesaro in 2018, along with other oncology drug candidates, including latecomer PD-1 inhibitor Jemperli (dostarlimab) and others ...

Discover GSK's impressive stock surge, boosted by strong earnings, a share buyback program, and a focus on specialty medicines.

GSK started an international phase 1 trial of the drug last summer. Osteosarcoma mainly affects children and young adults and is the most common primary bone cancer, accounting for 20% to 40% of ...

Hesham Abdullah, GSK's Senior Vice President, Global Head Oncology R&D, stated, "This acquisition adds to GSK's growing pipeline of targeted therapeutics for cancers originating in the ...

GSK's revenue and EPS exceeded my expectations and those of analysts, thanks to the strong performance of its oncology and HIV franchises. So, Ojjaara/Omjjara sales amounted to $150 million in the ...

having been knocked back by US lawsuits over the alleged cancer risks of discontinued heartburn drug Zantac. Even after GSK reached a $2.2bn settlement in October, resolving the majority of cases ...